I asked Trius IR about not tendering shares and what would happen. This is what I got back.
Thank you for your inquiry.
If you do not tender your shares and the deal goes through you will receive the $13.50 per share and the CVR.
More information may be found at investor.triusrx.com/sec.cfm
Hillary Theakston
Investor Relations for Trius
htheakston@triusrx.com
(858) 452-0370 x440
So it DOES look like we'll be paid out those shares at the current deal's specifics; which is nice.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM